Chiasma (NASDAQ: CHMA) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Analyst Recommendations

This is a summary of current ratings and target prices for Chiasma and Argos Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Chiasma 1 0 0 0 1.00
Argos Therapeutics 0 3 0 0 2.00

Argos Therapeutics has a consensus price target of $4.13, indicating a potential upside of 2,278.21%. Given Argos Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Argos Therapeutics is more favorable than Chiasma.

Insider & Institutional Ownership

50.4% of Chiasma shares are held by institutional investors. Comparatively, 27.9% of Argos Therapeutics shares are held by institutional investors. 3.2% of Chiasma shares are held by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Chiasma has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Profitability

This table compares Chiasma and Argos Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Chiasma N/A -35.96% -31.97%
Argos Therapeutics -12,391.15% -1,532.49% -92.03%

Valuation and Earnings

This table compares Chiasma and Argos Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Chiasma N/A N/A -$29.42 million ($1.27) -1.89
Argos Therapeutics $485,347.00 19.69 -$44.47 million ($1.48) -0.12

Chiasma has higher revenue, but lower earnings than Argos Therapeutics. Chiasma is trading at a lower price-to-earnings ratio than Argos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Chiasma beats Argos Therapeutics on 6 of the 11 factors compared between the two stocks.

Chiasma Company Profile

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.